Baricitinib therapy for Rheumatoid Arthritis: an Observational Study
Research type
Research Study
Full title
A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies
IRAS ID
249435
Contact name
Tom Sheeran
Contact email
Sponsor organisation
Eli Lilly and Company
Duration of Study in the UK
6 years, 3 months, 31 days
Research summary
The purpose of this study is to assess the effectiveness of Olumiant (baricitinib) and certain other treatments for rheumatoid arthritis and the effect, if any, on physical functioning, quality of life, and pain associated with rheumatoid arthritis. The healthcare resources required for treating and managing rheumatoid arthritis and the associated costs will also be explored.
This is an observational study. There are no experimental treatments involved, and there will be no additional tests or clinic visits required. Participants will only be undergoing standard of care treatment.
About 200 clinics in 9 countries across different parts of the world will provide information on their participants for this study. There will be approximately 1840 participants in this study.
REC name
South West - Frenchay Research Ethics Committee
REC reference
18/SW/0214
Date of REC Opinion
14 Sep 2018
REC opinion
Favourable Opinion